Dupixent is attempting to expand insurance reimbursement to infants after succeeding to reimburse the drug to children.

Dailpharm’s coverage showed that Sanofi-Aventis Korea recently submitted an application for an extension of reimbursement for infants aged 6 months to 5 years of age for its atopic dermatitis treatment Dupixent (dupilumab).

Whether Dupixent, which has succeeded in expanding reimbursement to the long-awaited children and adolescent indication this month, will be able to expand its prescription area once again is gaining attention.

In November last year, Dupixent expanded its indication as an atopic dermatitis treatment to the treatment of moderate